Funding for this research was provided by:
European Society of Cardiology
Received: 11 December 2020
Accepted: 30 January 2021
First Online: 11 February 2021
Ethics approval and consent to participate
: Local Ethics Committees approval was obtained via the National Coordinators for each participating country in both surveys. Signed informed consent was obtained from each participant and stored locally in the patient file.
: Not applicable.
: GF, PV, DDB, GDB and DW have nothing to disclose.VG reports grants from Swedish Heart and Lung Foundation, during the conduct of the study; personal fees from MSD Sweden, personal fees from Novo Nordisk Sverige outside the submitted work.KK reports grants from European Society of Cardiology, during the conduct of the EUROASPIRE surveys.LM reports personal fees from Novo Nordisk, Sanofi Aventis, Astra Zeneca, MSD, Boehringer Ingelheim and Amgen outside the submitted work.AN reports personal fees from Astra Zeneca, MSD Sweden, Lilly, and Boehringer Ingelheim, outside the submitted work.JT reports grants and personal fees from Bayer Pharma, grants from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees from Glucolife PTE Ltd, grants and personal fees from Merck, and stock ownership of Orion Pharma and Glucolife PTE Ltd.LR reports grants from The Swedish Heart and Lung Foundation, Stockholm County Council (ALF), European Society of Cardiology, and Private Foundations during the conduct of the study.